Has OCS use for severe asthma in the US decreased in the last 10 years? - Vienna 2024

Precision medicine considerations and inhalation efficacy in airway diseases

Chair(s): Th?r?se Lapperre, Petros Bakakos

Session type: Poster session

Has OCS use for severe asthma in the US decreased in the last 10 years?

Aungkana Vichiendilokkul

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Expiratory Flow Limitation Development Index (EDI) measured by oscillometry in COPD

James Dean

Poster

Abstract

The effectiveness of discharge care bundles on reducing hospital readmissions in COPD; a systematic review

Siobhan Giblin

Poster

Abstract

Impact of varying health status thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis

David M. G. Halpin

Poster

Abstract

Impact on Quality of Life in Greek asthmatic patients receiving Budesonide/Formoterol FDC as maintenance treatment, with or without additional reliever treatment. Results from the NOTOS study.

Maria Bertoli

Poster

Abstract

Towards disease stability in COPD management: patient perspectives

Mark Brooke

Poster

Abstract

Evaluating asthma control in patients using Budesonide/Formoterol FDC as maintenance treatment, with or without reliever, in Greece. Results from the NOTOS study.

Maria Bertoli

Poster

Abstract

Narrative exploration of uncontrolled asthma: insights from patients and healthcare professionals in a cross-sectional study

Mattia Ramaccia

Poster

Abstract

Has OCS use for severe asthma in the US decreased in the last 10 years?

Aungkana Vichiendilokkul

Poster

Abstract

Asthma remission : how much can we improve?

Ana Rita Gaspar Ribeiro

Poster

Abstract

Patients’ perspectives and perceptions of asthma clinical remission: A global view

Stephen G Noorduyn

Poster

Abstract

Assessing the accuracy of pulse oximetry to detect severe hypoxemia in chronic lung disease patients using long term oxygen therapy

Bruno Deo De Oliveira

Poster

Abstract

Evaluating the influence of health policy on health outcomes: REALITI-A post hoc analysis

Rafael Alfonso-cristancho

Poster

Abstract

Treatable traits and personalised management of moderate-severe asthma: implications for reliever use, symptom control and exacerbation risk

Gabriel Garc

Poster

Abstract

Implementation of 2023 CTS guidelines for SITT could reduce exacerbation and mortality rates in COPD: PROMETHEUS Canada.

Mohit Bhutani

Poster

Abstract

The SHARP CRC Health Economics Study. Simulation of the preventable costs of oral corticosteroids in severe asthmatics in eleven European countries

Arnaud Bourdin

Poster

Abstract

What do patients really think of oral steroids for asthma attacks? A discrete choice experiment.

Imran Howell

Poster

Abstract

Potential reductions in COPD exacerbations, mortality, and costs due to increased SITT use in appropriate patients. PROMETHEUS Spain.

John Bell

Poster

Abstract

Identifying Patients Requiring Necessary Treatment in Mild to Moderate COPD

Zihui Wang

Abstract

Late Breaking Abstract - Dupilumab improves lung function and reduces exacerbations despite withdrawal of inhaled corticosteroids/long-acting beta agonists

Michael E. Wechsler

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}